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journal homepage: www.jfma-onl ine.comLETTER TO THE EDITORReply to “Alanine transaminase as a
single marker is not reliable for selecting
candidates of pegylated interferon
and ribavirin treatment”To the Editor,
Sharafi et al had some concerns about our study design
because we excluded patients who had normal liver
enzyme. We agree that certain sample selection biases may
exist in our study.1 The current health care system in
Taiwan, known as the National Health Insurance (NHI), is a
compulsory program providing universal and quality health
care to the people of Taiwan at affordable costs. Taiwan’s
Bureau of National Health Insurance launched the National
Antiviral Treatment Program in 2003 to reimburse patients
for expenses related to antiviral drugs and interferons for
the treatment of chronic hepatitis B and C. During the
period from 2009 to date, the Taiwan NHI program only
reimbursed interferon therapy for chronic hepatitis C pa-
tients with a compensated liver condition who received
treatment with pegylated interferon (PEG-IFN) and ribavirin
when alanine transaminase (ALT) elevation plus hepatitis C
virus (HCV) was RNA positive, or METAVIR system  F1 was
proved by liver biopsy. Concerning the financial burden on
these patients, we treated only those patients with hepa-
titis C infection and an elevated ALT level who fitted the
Taiwan NHI chronic hepatitis C treatment criteria.Conflicts of interest: The authors have no conflicts of interest relev
http://dx.doi.org/10.1016/j.jfma.2014.05.006
0929-6646/Copyright ª 2014, Elsevier Taiwan LLC & Formosan MedicaIn Fig. 1, the percentage of patients who completed
the treatment course shown was incorrect. The correct
percentage should be 63%, as shown in the modified
Fig. 1.
Our study focused on the efficacy and safety of PEG-IFN
and ribavirin in hemophilic patients with hepatitis C
infection. As per Alavian et al’s study,2 HCV RNA level has
a significant impact on sustained viral response (SVR) in
hemophilic patients with HCV infection who were treated
with PEG-IFN and ribavirin. However, we did not discuss
the relationship between HCV RNA level and treatment
efficacy because of our small sample size. A large-scale
multicenter study in hemophilic patients with HCV infec-
tion in Taiwan is needed to better understand the impact
of HCV RNA level on SVR in hemophilic patients with HCV
infection who were treated with PEG-IFN and ribavirin.
Finally, we also agree to the fact that ALT level as a single
marker in patients with chronic HCV infection cannot be
reliable enough to be considered in making the clinical
decision regarding the start of treatment. When transient
elastography (Fibroscan) is available, patients with liver
fibrosis should receive treatment regardless of liver
enzyme.ant to this article.
l Association. All rights reserved.
Figure 1 Flow diagram of the trial. ALTZ alanine aminotransferase; ETRZ end of treatment response; EVRZ early virological
response; HCV Z hepatitis C virus; HIV Z human immunodeficiency virus; IFN Z interferon.
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